Biotickr logobiotickr

Atossa Therapeutics Inc

The ATOS stock trades on Nasdaq All Markets

Company Description

Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. We believe our innovative therapies and delivery methods can benefit COVID-19 patients and transform breast cancer treatment – with the goal of preventing breast cancer from developing in the first place.

We have two COVID-19 therapeutic programs under development, one for severely ill patients on ventilators and another for at-home use in patients recently diagnosed with COVID-19 who do not require hospitalization. We are also developing a drug “endoxifen” to reduce mammographic breast density and, for patients who have recently been diagnosed with the most common type of breast cancer, to reduce tumor activity prior to surgery. Approximately one in eight women and one in 1,000 men will be diagnosed with breast cancer during their lifetime. Every two minutes an American woman is diagnosed with breast cancer; 40,000 die each year. The American Cancer Society (ACS) estimates that approximately 270,000 women will be diagnosed with breast cancer in the United States this year. It is the second leading cause of cancer death in American women.

Drug Pipeline

Source: Atossa Therapeutics Inc - 20220924
Phase 1
Breast Cancer
Phase 2


0 following
Messages Image
Log in or sign up to join the conversation.

0 Comments on ATOS stock